Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by bringon10baggeron Feb 13, 2021 1:18pm

233 Views

Post# 32562069

Global NSAID Sales Growing

The global non-steroidal anti-inflammatory drugs (NSAIDs) market is set to gain momentum from the ever-increasing research activities by several prominent pharmaceutical companies on selective cyclooxygenase-2 inhibitors as they are still a grey area for these companies. Tough, NSAIDs such as ibuprofen and diclofenac are nowadays used to hinder the activity of COX, but they have undesirable effect. Fortune Business Insights™ published this information in a new report, titled, “Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Size, Share & Industry Analysis, By Disease Indication (Arthritis, Migraine, Ophthalmic Diseases, and Others), By Route of Administration (Oral, and Parenteral), By Distribution Channel (Hospital Pharmacy Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2020-2027.” The report further mentions that the NSAIDs market size was USD 15.58 billion in 2019 and is projected to reach USD 24.35 billion by 2027, exhibiting a CAGR of 5.8% during the forecast period.

PICK the Winner......

Fortune Business Insights™ lists out the Key Companies Operating in the NSAIDs Market. They are as follows: